Legal Operations for Life Sciences and MedTech in the EU

The evolving EU life sciences and medtech regulatory landscape

Over the past decade, the European Union has embarked on a significant overhaul of its legal framework for medicines, medical devices, and diagnostics, driven by technological innovation and safety incidents. The long-standing directives were replaced by directly applicable regulations, namely Regulation (EU) 2017/745 on medical devices (MDR) and Regulation (EU) 2017/746 on in vitro diagnostic devices (IVDR).

To prevent shortages of essential diagnostics, the EU adopted Regulation (EU) 2024/1860 in June 2024, extending transitional periods and mandating the gradual roll-out of EUDAMED modules. Under the IVDR, obligations are reshaped across the entire supply chain, introducing a risk-based classification system and extending notified body involvement to most diagnostics.

These reforms require manufacturers to redesign their internal compliance processes, particularly around technical documentation, performance evaluation, and lifecycle vigilance.

In parallel, the Clinical Trials Regulation (EU) No 536/2014 (CTR) has fully replaced the previous clinical trials directive. As of January 31, 2025, all ongoing clinical trials in the EU must have successfully migrated to the Clinical Trials Information System (CTIS), making the CTR the sole applicable regime.

By introducing a single EU portal and harmonised assessment procedures, the regulation has transformed how sponsors manage clinical trials. This centralization is accompanied by strict transparency rules, with most submitted information becoming publicly accessible, requiring aligned legal and regulatory strategies.

At the same time, the EU has adopted Regulation (EU) 2021/2282 on health technology assessment (HTA), creating a framework for joint clinical assessments (JCAs) for designated health technologies. Applying fully from January 12, 2025, developers submitting marketing authorisation applications for oncology medicines and advanced therapies must provide specific clinical documentation. This dual pathway amplifies the need for coordinated legal operations, as product dossiers must be consistent across European Medicines Agency (EMA) evaluation and national reimbursement negotiations.

Recognising the strategic importance of these sectors, the European Commission has articulated a new life sciences strategy aimed at making Europe the most attractive place for life sciences by 2030. This strategy proposes measures along the entire value chain, including an investment plan for multi-country clinical trials and a planned Biotech Act.

For medical technology, MedTech Europe has urged policymakers to ensure the sector is integrated into this future strategy. They highlight the need for structural reform of the device regulatory system, streamlined requirements across policy domains, and strategic investment in resilient healthcare infrastructures.

Together, these policy initiatives signal a tighter regulatory environment, expecting companies to adapt their legal and operational capabilities to participate in a coordinated European innovation ecosystem.

From legal compliance to legal operations

Historically, many life sciences and medtech organisations treated regulatory compliance as a specialised function largely confined to regulatory affairs and external counsel. In practice, however, the most persistent problems emerge at the interfaces between corporate disciplines.

This occurs when clinical teams plan trials without anticipating evolving GCP requirements, or engineering teams introduce AI features without mapping AI Act implications. In an international environment, legal risk often arises from fragmented processes, inconsistent documentation, and the absence of a centralized view of cross-border data flows.

This shift from a narrow compliance mindset to a broader legal operations perspective aligns with developments across corporate legal departments. Legal operations encompasses the design, implementation, and continuous improvement of processes, tools, and governance mechanisms that enable compliance functions to support business objectives efficiently.

For life sciences and medtech companies in the EU, this means embedding regulatory obligations into standard operating procedures and managing inspection readiness. Increasingly, it also involves leveraging digital tools and AI to manage growing volumes of documentation and regulatory interactions.

Medical devices and in vitro diagnostics as operational drivers

The MDR and IVDR form the backbone of EU regulation for medical devices and diagnostics, driving the legal operations agenda of any manufacturer on the EU market. Unlike the previous directives, these regulations are directly applicable and significantly expand the scope of quality management and clinical evaluation obligations.

They also introduce strict expectations for economic operators throughout the supply chain, including manufacturers, authorised representatives, importers, and distributors. This creates a highly complex network of shared and overlapping responsibilities.

For in vitro diagnostics, the IVDR introduces a risk-based classification system with four classes, linked to potential patient and public health impact. Under this framework, most diagnostics now require the involvement of a notified body, shifting from fifteen percent to approximately eighty to ninety percent.

This change has profound operational implications for manufacturers, who must manage complex conformity pathways and maintain comprehensive technical documentation. This must be closely coordinated under resource constraints due to limited notified body capacity.

A key feature of the IVDR is the emphasis on robust performance evaluation, structured around scientific validity, analytical performance, and clinical performance. Scientific validity requires evidence of clinical association, analytical performance demands accuracy data, and clinical performance requires evidence of intended correlation.

These elements must be detailed in a Performance Evaluation Plan and Report within the technical documentation. From a legal operations perspective, this requires coordinated workflows between R&D, clinical affairs, and legal teams to align evidence strategies with regulatory timelines.

The MDR places similar emphasis on clinical evaluation for medical devices, defined as a systematic process of collecting and assessing clinical data. Manufacturers must prepare a Clinical Evaluation Plan and Report, which are subject to notified body review for most devices.

The report must demonstrate sufficient clinical evidence to support conformity with safety and performance requirements. It must also be regularly updated to reflect new data from post-market surveillance, requiring sustained operational attention and data management.

Recent guidance from the Medical Device Coordination Group (MDCG) on post-market surveillance under the MDR and IVDR further elaborates these expectations. Manufacturers must establish and maintain a post-market surveillance (PMS) system integrated into their quality management system, proportionate to device risk.

The PMS system must drive systematic data collection on safety, feeding into updates of technical documentation and clinical evaluations. Operationalising this guidance requires robust data collection mechanisms, clear internal responsibilities, and documented decision-making processes.

The European Commission has also adopted implementing regulations to harmonise uniform requirements for conformity assessment and notified bodies under the MDR and IVDR.

Clinical trials: CTR, CTIS, and modernised Good Clinical Practice

The Clinical Trials Regulation aims to harmonise and streamline the conduct of interventional clinical trials with medicinal products across the EU. Its central innovation is the requirement that sponsors submit a single clinical trial application via the CTIS portal, leading to a single decision per Member State.

This replaces the previous fragmented national submissions regime and facilitates multinational trials. From January 31, 2025, when the transition period concluded, all ongoing clinical trials in the EU must operate under the CTR and utilize CTIS for life-cycle management.

The regulation introduces significant transparency obligations, with the default expectation that information in the EU database is made public. The European Medicines Agency has adopted revised CTIS transparency rules, effective from June 2024, detailing how data is made accessible.

Legal operations in sponsoring organisations must account for this public visibility when drafting protocols and informed consent documents. They must coordinate closely with communications and intellectual property functions to manage confidentiality claims appropriately.

The regulation also simplifies safety reporting by allowing trial protocols to specify that not all adverse events need to be systematically recorded. Suspected unexpected serious adverse reactions must be reported via EudraVigilance, aligning pharmacovigilance with trials oversight. This requires robust pharmacovigilance interfaces to ensure safety obligations are met.

Inspection dimensions are equally critical, with detailed arrangements provided for Good Clinical Practice (GCP) inspection procedures. The European Commission may conduct controls to verify that Member States supervise compliance and may verify third-country regulatory systems for equivalence.

Moreover, clinical trials conducted outside the EU but submitted in support of EU marketing authorisations must adhere to equivalent principles. This global reach means that legal operations must extend beyond EU borders, aligning contractual frameworks with international partners.

Concurrently, the International Council for Harmonisation (ICH) has revised its foundational GCP guideline, ICH E6, to version R3. The new guideline introduces an overarching principles document alongside annexes addressing both traditional and non-traditional trial designs.

These updated principles emphasize proportionate, risk-based approaches to trial design, embedding quality-by-design concepts. Legal operations functions must adapt standard operating procedures and contract templates to reflect these evolving expectations, particularly when piloting digital tools.

EMA-coordinated inspections and lifecycle compliance

The European Medicines Agency coordinates inspections for medicines authorised under the centralised procedure, though inspections are carried out by national authorities. These inspections cover a broad range of compliance domains, including good manufacturing, clinical, and laboratory practices.

From a legal operations perspective, the key feature of this inspection framework is its lifecycle coverage and cross-border reach. Manufacturing sites anywhere in the world producing medicines for the EU market are subject to GMP inspections, with particular attention to sites in countries without mutual recognition.

Pharmacovigilance inspections can target any party involved in safety monitoring, regardless of location, acting on behalf of authorisation holders. Non-compliance findings typically lead to corrective action plans, with potential implications for supply and authorisation status.

Coordinating responses to such inspections requires integrated legal operations that can quickly assemble documentation and ensure consistent narratives. EMA also runs a sampling and testing programme to confirm the quality of authorised medicines on the market, reinforcing the need for robust quality systems.

Health technology assessment: joint clinical assessments as a parallel track

The EU’s HTA regulation introduces a new layer of structured evidence assessment at the European level, with joint clinical assessments (JCAs). JCAs provide scientific analyses of clinical evidence on relative effects, supporting national HTA processes without replacing domestic decision-making.

From January 12, 2025, JCAs apply directly to new oncology medicines and advanced therapies submitted to the EMA. The scope is scheduled to expand to orphan products in 2028, and to all centrally authorised medicines and certain high-risk devices by 2030.

Operationally, health technology developers must submit clinical documentation to the HTA secretariat, synchronised with their EMA submissions. Developers must upload relevant documentation within specified timelines, with a strict prohibition on using unsecured email.

This emerging HTA framework requires legal operations to integrate the HTA coordination group into regulatory planning. Documentation must be aligned across EMA and HTA processes, and internal governance must ensure clinical development plans anticipate both regulatory approval and national reimbursement.

The AI Act and AI in healthcare

Artificial intelligence plays a growing role both in medical products and in internal legal and compliance workflows. In August 2024, the European AI Act entered into force, establishing a risk-based framework that imposes stringent requirements on high-risk AI systems, including many medical software applications.

High-risk AI obligations include risk-mitigation systems, high-quality training datasets, transparency, and human oversight. The Act also treats developers of software as manufacturers for regulatory purposes when their AI systems are embedded into regulated products.

In the healthcare context, AI-based software qualifying as a medical device under the MDR or IVDR will often be considered high-risk under the AI Act. This is particularly true when the device is in a class requiring notified body involvement and the AI acts as a safety component.

Consequently, there are relatively few AI-based medical devices that escape this regime, requiring manufacturers to integrate AI Act compliance into device conformity strategies.

It is clinically and operationally vital to recognize that the applicability timeline for the AI Act varies: while general prohibitions apply from February 2025, and general-purpose AI rules from August 2025, high-risk AI systems serving as safety components of medical devices are subject to a transitional period of 36 months under Article 113(3), making full compliance mandatory in August 2027.

The AI Act also foresees a Code of Practice for providers of general-purpose AI models, expected to address transparency, copyright, and risk management. This has implications not only for AI embedded in products, but also for AI tools used in legal and compliance functions.

In-house counsel considering AI-based tools for research, contract analysis, or workflow automation must navigate confidentiality, privilege, and data transfer concerns. Legal operations must therefore encompass both outward-facing compliance for AI products and inward-facing governance of internal tools.

Data protection and clinical research data

Clinical research and post-market surveillance activities generate highly sensitive health data, often across borders and over extended periods. The General Data Protection Regulation (GDPR) applies to EU-based sponsors and vendors, as well as non-EU organisations processing data of EU participants.

In practice, sponsors must ensure lawful bases for processing, implement appropriate technical measures, and uphold data subject rights throughout the data lifecycle. This requires balancing consent rules with public interest or scientific research exceptions depending on Member State implementation.

A particular challenge arises from the long-term retention requirements for clinical research data, driven by regulatory obligations and inspections. Under the CTR, clinical trial master files must be archived for at least 25 years, making GDPR compliance a continuous obligation.

Maintaining a minimum governance structure, including the ongoing appointment of an EU-based Data Protection Officer and a local representative, is essential. Legal operations must ensure that retention policies, contracts with service providers, and internal processes reflect these extended timelines.

Sensitive patient data requires strict confidentiality and integrity safeguards, as non-compliance risks include administrative fines and delays in study approvals. Sensitive patient data requires strict confidentiality and integrity safeguards, as non-compliance risks include administrative fines and delays in study approvals.

This is particularly relevant when clinical trials and post-market studies rely on decentralised elements or real-world data sources. Legal operations must coordinate impact assessments, records of processing activities, and contractual arrangements to ensure obligations are clearly allocated.

Ethical promotion and interactions with healthcare stakeholders

Beyond product and research regulation, life sciences companies must navigate ethical rules governing interactions with healthcare professionals, organisations, and patient groups. Industry codes of practice, such as the EFPIA Code, establish ethical principles for promotion and engagement across both traditional and digital channels.

One concrete example is the EFPIA Code's restriction on providing meals to healthcare professionals or patient representatives. Member companies must not offer meals exceeding monetary thresholds set by national associations, with a host-country principle governing which code applies.

Such operational details can have significant compliance implications, particularly for multinational events and cross-border promotional activities. Legal operations must support the creation of internal policies, training, and approval workflows that reflect these requirements.

While EFPIA focuses on pharmaceuticals, similar ethical principles apply across the broader medical technology sector. Interactions with healthcare stakeholders increasingly fall under the scrutiny of regulators, payers, and the public through transparency registers and disclosure obligations.

The primary operational challenge is coordinating multiple events, jurisdictions, and stakeholders, especially when digital tools amplify the scale of promotional activities. Legal operations must incorporate these monitoring and reporting systems into standard corporate compliance routines.

Transparency in clinical trials and product information

As noted above, the Clinical Trials Regulation and CTIS significantly expand the transparency of clinical trial information, making protocols and results public. Similarly, the MDR and IVDR strengthen transparency obligations for medical devices, including public access to safety and clinical performance summaries.

These transparency requirements intersect with intellectual property, trade secret protection, and reputational concerns, requiring strategic decision-making. Sponsors must decide which elements of investigational plans can be redacted as Commercially Confidential Information without undermining competitive positioning.

Legal operations must work closely with R&D, regulatory, and corporate communications to craft submissions that strike this balance. They must also monitor the timing of public releases to avoid inconsistencies or premature disclosures.

In practical terms, transparency obligations reinforce the need for structured documentation, version control, and centralised repositories. This is where having briefs and next steps in a single environment allows teams to see which materials are public and which remain confidential.

A combination of document centralisation, initial AI processing, and expert involvement within a secure digital workflow proves highly effective. This approach maintains consistency and traceability across submissions, updates, and public disclosures.

AI for in-house legal and compliance teams

Legal departments in life sciences and medtech companies increasingly explore AI-based tools to enhance productivity and streamline workflows. These tools can assist with legal research, contract drafting, regulatory monitoring, and e-discovery, offering potential time savings and improved consistency.

For instance, AI models can rapidly scan large volumes of regulatory guidance to identify emerging expectations. Similarly, AI-driven contract analytics can flag clauses related to governing law, liability, and data protection, enabling more focused review and negotiation.

However, integrating AI into legal practice raises significant issues around confidentiality, privilege, and data protection. Counsel remain responsible for protecting client confidentiality and ensuring that privileged information is not inadvertently disclosed or compromised.

Uploading sensitive documents or clinical trial agreements into public AI platforms without appropriate safeguards could constitute a waiver of privilege. Legal operations must therefore establish clear policies for AI use, vetting vendors' data handling practices and configuring tools securely.

Cross-border data transfer considerations compound these challenges, particularly when AI vendors host infrastructure outside the EU. Legal operations must assess data localisation, transfer mechanisms, and contractual guarantees, often in coordination with data protection officers and security teams.

Platforms like Anywhere.legal resolve these challenges by offering a centralized interface where secure AI tools support initial workflow efficiency while keeping all data strictly segregated and confidential. In this hybrid model, AI serves as an accelerated pre-processing tool, but final validation is always executed by vetted professional experts.

AI embedded in medical products and the intersection with MDR/IVDR

When AI is embedded in medical devices, legal operations must coordinate regulatory strategies across both product and AI-specific frameworks. Manufacturers must document risk management, dataset quality, human oversight, and post-market monitoring, in addition to traditional safety requirements.

A helpful way to conceptualise this is to view AI-based devices as sitting at the intersection of multiple regulatory streams. This includes device classification under MDR/IVDR, AI system requirements under the AI Act, and data protection under GDPR.

Legal operations must orchestrate these streams, ensuring that technical documentation, declarations of conformity, and certifications are consistent. This includes aligning contractual arrangements with suppliers of AI components, data providers, and notified bodies.

There will only be a limited subset of AI-enabled devices that escape high-risk classification under the AI Act. This would occur only where the device falls into Class I under the MDR and the AI does not serve as a safety component.

Legal operations must therefore adopt a cautious approach, treating AI governance as a core aspect of device lifecycle management. Even in such cases, organisational expectations from regulators and customers may effectively require similar governance.

Digital platforms and cross-border legal coordination

Digitalisation extends beyond AI to encompass broader platforms that centralise case management, document repositories, and communication. In cross-border life sciences, it is common to engage multiple local counsel, regulatory consultants, and CROs, each with their own communication channels.

The core operational problem usually does not arise in the legal assessment itself, but in coordinating these multiple parties. This fragmentation can lead to inconsistent advice, duplicated efforts, and missed deadlines.

Anywhere.legal addresses this specific need by serving as an integrated, multi-jurisdictional platform where enterprise legal, tax, and compliance challenges are coordinated in a single, secure environment.

When such platforms integrate AI capabilities for case scoping, they can help define briefs and identify relevant questions. AI-based document processors can summarise regulatory guidance and highlight gaps, allowing human experts to focus on strategic decisions.

In cross-border clinical trials, centralisation also facilitates consistent application of governing law clauses and compliance provisions. Digital platforms thus become operational tools that embed legal and regulatory requirements directly into day-to-day workflows.

Designing integrated post-market surveillance and quality systems

As emphasised by MDR, IVDR, and MDCG guidance, manufacturers must establish comprehensive post-market surveillance systems integrated into their quality management systems. These systems must gather, record, and analyse data on device quality, performance, and safety throughout the device lifetime.

They must draw systematically on sources such as complaints, incident reports, literature, registries, and follow-up studies. Legal operations play a central role in ensuring that these systems are not only technically robust, but also compliant with reporting obligations.

Manufacturers must produce post-market surveillance plans, define responsibilities, and maintain documentation of PMS activities, including periodic reports. Legal operations must ensure that PMS plans align with contractual commitments to partners and that vigilance obligations are properly allocated.

Internal escalation pathways must also allow timely reporting of serious incidents and field safety corrective actions to competent authorities. Section 5 of Annex XIII MDR explicitly requires manufacturers to report serious incidents as soon as they become aware of them.

Aligning PMS with quality systems also supports inspection readiness, as regulators may review PMS documentation as part of routine inspections. Legal operations must therefore maintain clear audit trails and provide oversight of corrective action plans.

In multinational organisations, managing these processes across subsidiaries and partner networks requires standardisation and central control. However, they must maintain sufficient flexibility to account for local reporting and language requirements.

Supply chain, distribution, and cross-border customs complexities

Medical devices and diagnostics often rely on multi-country supply chains with specific logistical and regulatory challenges. Trade lanes may involve long transit times, port congestion, and complex customs procedures, all of which can disrupt inventory availability and market access.

For devices requiring cold chain or controlled conditions, delays or non-compliance can compromise product quality and trigger liability. Legal operations must ensure that distribution agreements and quality agreements clearly allocate responsibilities for customs and temperature control.

They must also be aligned with good distribution practice (GDP) expectations, particularly where products are medicinal or combined products. Monitoring of supply chain risks may require digital tracking and coordinated contingency planning. From a contractual perspective, governing law clauses must be carefully selected to ensure enforceability across suppliers.

Cross-border tax governance, transfer pricing, and customs dynamics

A critical but frequently neglected aspect of life sciences legal operations is the interface between regulatory steps, corporate tax, and cross-border transfer pricing. In the EU, the movement of intellectual property, proprietary clinical trial data, and physical goods across borders triggers complex tax consequences that require proactive, multi-disciplinary coordination.

1. Transfer Pricing and DEMPE Functions: Under OECD Guidelines, profits from intangible assets are allocated based on where key value-creating activities are performed. If an EU subsidiary leads clinical trial management, but the IP is legally owned by a US parent, tax authorities will scrutinize whether the transactions are at arm's length. Legal operations must ensure that Intercompany Agreements (ICAs) align perfectly with actual clinical development.

2. Permanent Establishment (PE) Risks: Deploying clinical research associates, regulatory consultants, or medical scientific liaisons (MSLs) in other Member States can inadvertently create a dependent agent or fixed place of business Permanent Establishment for tax purposes. This exposes the parent company to corporate tax liabilities, payroll taxes, and filing obligations in host jurisdictions.

3. Indirect Tax (VAT) and Customs on Supplies: Clinical trial supplies shipped across borders require precise classification. Legal operations must align clinical supply agreements with Incoterms and clarify who acts as the Importer of Record. This is essential to avoid unexpected VAT burdens, customs holds, or the loss of input VAT recovery.

Because these tax risks can disrupt commercial viability as much as regulatory delays, Anywhere.legal operates as a dual-track ecosystem. Through its centralized environment, corporate clients can coordinate both their cross-border legal advice and their international transfer pricing, corporate tax, and VAT structuring, drawing on a vetted network of local tax attorneys and accountants to prevent compliance gaps.

Governing law and dispute resolution in cross-border contracts

Given the inherently cross-border nature of life sciences and medtech operations, governing law clauses play a central role in managing legal risk. Governing law refers to the body of law that will interpret the agreement, determine rights, and provide the dispute resolution framework. Parties commonly specify this choice in a dedicated clause.

Effective legal operations require a structured approach to selecting governing law, taking into account factors like system predictability and enforceability of remedies. Legal operations teams must maintain playbooks and templates that reflect organisational preferences and risk tolerances. At the same time, they must allow for negotiation flexibility in different markets.

Moreover, consistency in governing law and jurisdiction choices across contracts facilitates portfolio-level risk management. When contracts are negotiated independently by different business units, central legal operations must provide oversight to avoid conflicting frameworks.

This coherence is essential when managing coordinated regulatory responses, recalls, or litigation across jurisdictions. Unifying these agreements under a standardized legal operations strategy dramatically reduces corporate vulnerability.

Multi-disciplinary legal services and coordination

Life sciences law practice in Europe has become increasingly multi-disciplinary, integrating regulatory, corporate, tax, competition, and data protection expertise. For in-house legal operations, this complexity translates into a need for structured collaboration with external counsel across specialisations and jurisdictions.

Platforms and networks that connect clients with vetted local experts can support this coordination across Member States. Working across multiple jurisdictions, specialized firms combine regulatory experience with deep sector knowledge. Legal operations must decide when to rely on such external expertise and how to manage documentation.

In practice, the bottleneck is often not the availability of expert advice, but the organisation’s ability to structure the brief. This requires assembling relevant documents and defining clear questions that cut across disciplines and jurisdictions.

This is exactly where a combination of centralised document management, AI-assisted scoping, and collaborative workflows becomes valuable. This ensures that local experts receive complete instructions, and that their insights are integrated into a consistent framework.

Comparative overview of key regulatory drivers and operational responses

Scenario 1: Launching an AI-enabled in vitro diagnostic across the EU

Consider a European diagnostics company developing an AI-enabled in vitro diagnostic for cancer screening, intended for use in multiple EU Member States. Under the IVDR, the device is classified as class C due to its role in screening for serious disease and because the AI algorithm directly influences diagnostic output.

Notified body involvement is mandatory, and the manufacturer must prepare comprehensive technical documentation, including a Performance Evaluation Plan. The regulatory affairs team must align device classification with AI Act timelines—anticipating the August 2027 deadline—while clinical teams design validation studies that satisfy both frameworks.

From a legal operations perspective, coordinating these requirements demands an integrated project governance structure. Legal operations must oversee contracts with clinical sites and AI developers, ensuring appropriate allocation of liability, data protection obligations, and IP rights. They must also manage GDPR compliance for patient data used in algorithm training, including cross-border data transfers.

As the product approaches market roll-out, legal operations must coordinate with commercial teams to develop information for healthcare professionals. This information must meet transparency obligations under MDR/IVDR while accurately describing AI capabilities and limitations.

Preparing for post-market surveillance involves establishing mechanisms to collect performance data, monitor algorithm drift, and trigger corrective actions. A centralised digital platform that captures technical documentation and regulatory submissions can help maintain a coherent audit trail.

Preparing for post-market surveillance involves establishing mechanisms to collect performance data, monitor algorithm drift, and trigger corrective actions, ensuring that any necessary adjustments feed directly back into the design loop.

Scenario 2: Coordinating a multi-country oncology trial under CTR and HTA

A pharmaceutical company plans a multi-country oncology trial in support of an EMA marketing authorisation application for a biologic therapy. Following the expiration of the CTR transition period, the sponsor must submit a single clinical trial application via CTIS.

This requires harmonised documentation for all concerned Member States, including protocol, investigator's brochure, and informed consent forms. In the trial design phase, they must ensure that endpoints not only satisfy regulatory requirements, but also generate evidence relevant for HTA evaluations.

Legal operations must orchestrate a timeline that accounts for both regulatory pathways. Contracts with investigative sites and CROs must incorporate obligations to collect and share data in formats that feed directly into HTA dossiers. This must be managed while maintaining strict alignment with data protection and ethical standards.

From a cross-border tax perspective, payments to local clinical trial sites and principal investigators must be structured carefully to manage withholding tax (WHT) obligations and prevent permanent establishment (PE) tax exposures for the sponsor in foreign Member States.

During trial conduct, legal operations must monitor CTIS communications, coordinate responses to ethics committee questions, and ensure consistent implementation of protocol amendments. They must also manage transparency considerations, knowing that certain trial documents will become publicly accessible.

As the marketing authorisation application approaches, legal operations must ensure that the clinical overview submitted to EMA is consistent with HTA documentation. This scenario illustrates how legal operations must operate at the nexus of regulatory, HTA, data protection, and contractual frameworks.

Scenario 3: Managing a post-market safety signal and cross-border field action

A medical device manufacturer discovers a safety signal related to a class IIb implantable device, indicating a potential increase in failure rates in certain batches. The device is marketed in multiple EU Member States, with manufacturing in a third country and distribution through regional partners.

First, the manufacturer must determine whether the safety issue constitutes a serious incident requiring notification and whether a field safety corrective action is necessary. Legal operations must ensure that incident reports are submitted to the appropriate authorities in each Member State where the device is marketed.

At the same time, legal operations must review contracts with manufacturing partners, distributors, and insurers to understand recall obligations and liabilities. From an indirect tax perspective, a mass recall requires coordination with logistics to manage VAT implications on returned goods and reverse logistics documentation.

The PMS system must be updated with investigation findings, and risk management files must be revised to reflect new knowledge, potentially triggering design changes. National authorities may initiate inspections, requiring legal operations to assemble documentation demonstrating due diligence and corrective action implementation.

EU life sciences strategy and policy coherence

The EU's life sciences strategy seeks to position Europe as a global leader by 2030 by addressing weaknesses along the innovation and market access value chain. The strategy proposes optimising the research ecosystem through EU investment plans for multi-country clinical trials.

It also envisages an EU Biotech Act to create an innovation-friendly framework, and a matchmaking interface to connect start-ups with investors. They argue for structural reforms of the device regulatory system, better alignment across policy domains, and strategic investments in healthcare infrastructure.

MedTech Europe has responded by emphasising that medical technology must be an integral part of this future life sciences strategy. For legal operations in medtech companies, these debates translate into continued regulatory flux, but also potential opportunities to engage in policy shaping.

Anticipating future reforms can help companies adapt compliance pathways or leverage new support mechanisms.

Modernised GCP and decentralised trials

The adoption of ICH E6(R3) reflects a global shift towards more flexible, risk-based approaches to clinical trials, including pragmatic designs and decentralised models. The new guideline's principles emphasise that clinical trials should be scientifically sound and proportionate to the risks involved.

For legal operations, this evolution means that traditional SOPs and contract templates may no longer suffice. Agreements with investigative sites and technology providers must account for remote monitoring, home-based interventions, and increased reliance on digital infrastructure.

Data protection and cybersecurity considerations become even more prominent when trial data flows through multiple digital channels. Legal operations must thus stay abreast of evolving guidance, pilot new models, and capture lessons learned in updated policies.

AI governance and cross-regime convergence

The AI Act represents one of the first comprehensive attempts globally to regulate AI across sectors, and its interaction with sectoral frameworks illustrates the complexity of cross-regime convergence. Legal operations must navigate overlapping obligations, such as aligning AI risk management with device risk management.

Moreover, the planned Code of Practice for general-purpose AI models and emerging guidance on AI in healthcare mean that AI governance will remain a moving target. Legal operations must establish agile governance structures incorporating cross-functional committees and AI inventories.

Training for legal, regulatory, and technical staff will be essential to ensure that AI-related obligations are understood and correctly implemented. This proactive approach ensures compliance while supporting technological innovation across the organization.

Conclusion

The regulatory environment for life sciences and medical technology in the European Union has become both more sophisticated and more demanding. Reforms in medical device regulation, clinical trials, health technology assessment, data protection, and artificial intelligence are all converging on companies' operations.

MDR and IVDR have expanded obligations across the device lifecycle, requiring robust clinical evaluation and integrated post-market surveillance. The AI Act, together with MDR/IVDR, pulls AI-enabled devices into a high-risk regulatory framework, demanding systematic risk management, transparency, and human oversight.

In parallel, GDPR and ethical codes such as the EFPIA Code frame data protection and stakeholder interactions. EMA-coordinated inspections across GMP, GCP, and pharmacovigilance underscore that compliance must be maintained throughout the product lifecycle and across global supply chains.

Neglecting these intersecting frameworks carries significant operational and financial risks. Anywhere.legal addresses this specific need by serving as a centralized, secure digital ecosystem that coordinates multi-jurisdictional legal and tax workflows.

To address these challenges, life sciences and medtech companies must treat legal compliance as a strategic, operational function rather than a series of isolated tasks. Effective legal operations integrate regulatory, clinical, tax, quality, and commercial considerations across the product lifecycle, supported by centralised documentation and clear governance.

Need international legal help? Get in touch with us via Anywhere.legal.

FAQ

1. How do MDR and IVDR change the way medtech companies should organise their legal operations?

MDR and IVDR significantly increase the documentation, evidence, and lifecycle surveillance obligations on manufacturers, making ad hoc or reactive compliance approaches untenable. Legal operations need to work closely with regulatory affairs and quality teams to design integrated workflows for clinical or performance evaluation, risk management, and post-market surveillance, ensuring that technical documentation remains current and consistent. Under recent amendments like Regulation (EU) 2024/1860, companies must also adapt to mandatory reporting of supply interruptions and the phased rollout of EUDAMED modules. Central coordination across affiliates and partners is essential to maintain harmonised practices across the EU.

2. What are the main implications of the Clinical Trials Regulation and CTIS for sponsors' legal teams?

The CTR mandates that all clinical trials—including ongoing trials previously grandfathered under the old Clinical Trials Directive—must operate under the CTR and CTIS as of January 31, 2025. Legal teams must ensure that documentation is completely harmonised across Member States, that transparency considerations and redacting protocols for Commercially Confidential Information are built into the workflow, and that contractual agreements with sites and CROs reflect the shared responsibilities under the Regulation. Sponsors also need to adapt their safety reporting structures and inspection readiness plans to the Regulation's simplified but centralised regime. Overall, the Regulation elevates the importance of centralised trial governance and coordinated legal operations.

3. How does the AI Act interact with MDR/IVDR for AI-enabled medical devices?

AI-enabled devices that qualify as medical devices or in vitro diagnostics under MDR/IVDR and fall into classes requiring notified body involvement (Class IIa and above) are treated as high-risk AI systems under the AI Act. This means that manufacturers must comply with both device regulations and AI-specific requirements, including documented risk management, dataset governance, transparency, and human oversight. However, under Article 113(3) of the AI Act, manufacturers of devices requiring third-party assessment under MDR/IVDR have a transitional period of 36 months, making full compliance mandatory in August 2027. Legal operations must coordinate these obligations, ensuring that technical documentation, conformity assessments, and contracts with AI developers and data providers are aligned.

4. Why is GDPR compliance particularly complex in clinical research and post-market surveillance?

Clinical research and post-market surveillance involve long-term processing of sensitive health data, often across multiple countries and organisations, which amplifies GDPR compliance challenges. Sponsors must reconcile regulatory requirements for data retention (such as the CTR's 25-year archiving requirement) and transparency with data subject rights and security obligations, requiring carefully designed governance structures and contracts. Decentralised and digital trial models further complicate data flows, involving multiple controllers and processors and increasing cybersecurity risks. Legal operations must therefore integrate data protection impact assessments, robust records of processing, and clear roles and responsibilities into clinical and post-market workflows.

5. How can legal operations manage cross-border disputes, governing law issues, and tax risks in life sciences contracts?

Managing cross-border legal operations requires a multi-disciplinary approach. For contracts, legal operations should develop playbooks that guide the selection of predictable governing law and dispute resolution mechanisms, ensuring consistency across related agreements while accounting for mandatory local consumer or product liability laws. For tax, legal operations must ensure that intercompany licensing agreements and clinical supply agreements align with transfer pricing rules (OECD DEMPE functions) and local VAT requirements to prevent double taxation or customs holds during multi-country trials. Utilizing a centralized environment like Anywhere.legal ensures that legal drafting, local expert advice, and international tax structuring are coordinated hand-in-hand.